57 Results
Sort By:
Published on October 18, 2023
Precision medicines are gaining increasing traction in healthcare. Here are five companies driving the field with recent approvals in RNA therapeutics, cell and gene therapies, and more. Medicines have traditionally been given to patients in a one-size-fits-all approach, with many patients failing to benefit and experiencing side effects. This challenge…
Published on July 26, 2023
To better integrate precision medicine into the care they deliver, Children’s Hospital Colorado (Children’s Colorado) has launched a Precision Medicine Institute. The institute will use big data, including genomics, to determine “the best treatment for each patient,” according to a release. The effort is funded in part by a recent $5 million…
Published on July 11, 2023
Astellas Pharma and 4D Molecular Therapeutics (4DMT) just announced a license agreement giving Astellas rights to 4DMT’s intravitreal retinotropic R100 vector for use in gene therapy for a rare monogenic ophthalmic disease, with options to add up to two additional targets after paying additional option exercise fees. 4DMT will receive…
Published on June 8, 2023
Researchers at the Perelman School of Medicine at the University of Pennsylvania have received a seven-year, $6 million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to discover how the development and maintenance of heart cells is influenced by DNA. The hope…
Published on June 6, 2023
An analysis from the BabySeq Project, which trialed newborn sequencing in apparently healthy and unwell babies, found 17 infants with potentially pathogenic monogenic genetic findings that were all moderately or highly actionable. Of these infants, two-thirds were referred to specialist consultation, treatment or surveillance and all their at-risk first-degree relatives…
Published on April 27, 2023
Researchers have revealed how long sections of RNA that do not encode proteins can nonetheless impact on tissue function through their spatial position on chromosomes, which could have applications in targeting disease. Protein-coding genes account for less than two percent of the human genome and a large proportion of genetic…
Published on April 19, 2023
A study led by Yale University School of Medicine shows a significant link between prenatal depression and subsequent cardiovascular disease. The study was reported in the Journal of the American Heart Association and showed women who were depressed during pregnancy had a 32–83% increased risk of developing some form of…
Published on April 11, 2023
More than 20 years ago, the announcement of the completion of the first human genome was heralded, often breathlessly, as the dawn of a new age of medicine. But how far have we actually come in using an individual’s unique molecular make up to provide individually tailored care based on…
Published on March 29, 2023
Results from a study using artificial intelligence and magnetic resonance imaging show that heart shape can be an indicator of cardiac problems. The research, led by Cedars-Sinai Medical Center in Los Angeles and Stanford University and published in the journal Med, showed people with rounder shaped hearts were more likely…
Published on March 27, 2023
What should doctors do when patients have “incidental” findings of important variants related to cardiovascular disease? This is an increasingly important question as genome screens become more common both in the clinic and on the consumer market. A new scientific statement, published today in Circulation: Genomic and Precision Medicine, aims…
Published on February 10, 2023
The Genotype and Phenotype Database of Monogenic Cardiovascular Disease, or CardioGen, has been established by China’s BGI Genomics, together with the National Center for Cardiovascular Diseases, Fuwai Hospital, and the State Key Laboratory of Cardiovascular Diseases. CardioGen collects and integrates information about gene-causing diseases and clinical phenotype information of patients found in…
Published on December 30, 2022
Primera Therapeutics, the first launch from cell and gene therapy (CGT) accelerator Mayflower BioVentures, announced it has signed a collaborative agreement with Cellectis that will see the two companies will work to develop gene editing methods for mutations in mitochondrial DNA (mtDNA) as potential in vivo therapies to treat mitochondrial…
Published on December 20, 2022
With sequencing costs reportedly dropping to as low as $100 a genome, today’s medicine can enhance biological outcomes by harnessing data on genetic variation. A wealth of information on humanity’s responses to problems faced by some or all groups, such as aging, infectious diseases, diet, exercise, and smoking, is stored…
Published on August 5, 2022
A study published in the journal Science has challenged the idea that heart failure results from a common disease pathway, suggesting instead that individual genetics comes into play. The research revealed that genetic variants activate specific pathways in cardiomyopathies, some shared and some distinct, that resulted in different cellular landscapes…
Published on June 17, 2022
New European recommendations stress the value of cardiac genetic testing in athletes but also outline its limitations and the importance of counseling before and afterwards. High-level exercise can lead to structural and electrical changes in the heart that can mimic inherited cardiac conditions, explain the researchers. This ‘grey zone’ can…